|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.04.25 - 14:33
|
Clene to Present at the Emerging Growth Conference (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference....
|
|
|
01.04.25 - 14:33
|
Clene to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings....
|
|
|
|
|
|
|
|
|
24.03.25 - 13:03
|
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS....
|
|
|
|
|
|
|
|
|
06.03.25 - 14:33
|
Clene to Present at the 37TH Annual Roth Conference (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings....
|
|
|
27.02.25 - 15:27
|
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 (Accesswire)
|
|
|
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Rob Etherington, CEO, and Morgan Brown, CFO, of Clene Inc., will be presenting at this year's Investor Summit Virtual on March 11th.About Clene ......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
